# Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma

Source: https://onco.cc/key-papers/paper-wysong-40-gene-cutaneous-scc-j-am-acad-dermatol-2021/  
OnCo record `paper-wysong-40-gene-cutaneous-scc-j-am-acad-dermatol-2021` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The validation of a 40-gene test in high-risk squamous cell skin cancer, which separated three groups by their chance of spread.

## Summary

Three-year metastasis-free survival rates were 91.4, 80.6 and 44.0 per cent for classes 1, 2A and 2B.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Journal of the American Academy of Dermatology
- Year: 2021
- DOI: 10.1016/j.jaad.2020.04.088
- Authors: Wysong A, Newman JG, Covington KR, et al.
- Findings: Three-year metastasis-free survival 91.4%, 80.6% and 44.0% by class.
- What it means: A risk class exists; whether acting on it improves outcomes is not shown, and Medicare does not cover it.
- Caveats: Retrospective; industry-sponsored.

## Sources

- Wysong et al., J Am Acad Dermatol 2021: https://doi.org/10.1016/j.jaad.2020.04.088
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32344066/

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [DecisionDx-SCC](https://onco.cc/drugs/decisiondx-scc/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-wysong-40-gene-cutaneous-scc-j-am-acad-dermatol-2021.json